Heart Failure with preserved ejection fraction (HFpEF)

Size: px
Start display at page:

Download "Heart Failure with preserved ejection fraction (HFpEF)"

Transcription

1 Heart Failure with preserved ejection fraction (HFpEF) Dr. Pierpaolo Pellicori Hull York Medical School Kingston-upon-Hull United Kingdom Conflict of interest: none

2 Heart failure is a contemporary problem Incidence:- Many people in this room will develop some form of HF Prevalence (depending on definition):- ~3% of adults have some objective evidence ~25% of patients aged >50 years with T2DM or Hypertension ~50% (or more?) of patients with AF

3

4 Chan,Lam. EJHF Ather, JACC 2012

5 Typical HFPEF Patient Female, in her 70-80s Clinical history of HTN Breathlessness Peripheral oedema and raised JVP 40% AF on ECG NTproBNP above 1000 ng/l (normal < 125 ng/l) IVC (& intrahepatic veins) distended Anaemia and CKD

6

7 How to diagnose HFpEF? 2012 ESC-HF guidelines

8 Key echo structural alterations: left atrial volume index (LAVI) >34 ml/m2 left ventricular mass index (LVMI) 115 g/m2 for males and 95 g/m2 for females. E/e 13 Mean e septal and lateral wall <9 cm/s

9 NTproBNP Marker of Congestion Strongest predictor of prognosis in CHARM-Preserved PEP-CHF I-PRESERVE Also increased with common co-morbidities Low egfr Atrial Fibrillation

10 Cleland et al.

11 SAVOR - TIMI 53 Risk of HF hosp according to NTproBNP > 50% NTproBNP > 125 ng/l # # 12% had previous HF diagnosis; 3% had previous HF hosp; AF not reported Scirica et al, /CIRCULATIONAHA

12 National heart failure audit

13 At echocardiography: LVEF might be normal Advanced echo (GLS): impaired LV longitudinal function Dilated left atrium and inferior vena cava (and raised NTproBNP) are powerful predictors of adverse outcome Pellicori P et al. Int J Cardiovasc Imaging. 2014;30(1):69-79

14

15 Cameli et al. Am J Cardiol 2013;111(4): Pellicori et al - Eur Heart J. 2015;36(12): Novel modalities Left atrial function?

16 Pellicori et al Int J Cardiol Jan 1;170(3): Pellicori et al Heart Jul;101(14): Novel modalities jugular vein ultrasound?

17 How to treat HFpEF? No treatment has yet been shown, convincingly, to reduce morbidity or mortality in patients with HFpEF. Screen for cardiovascular and non-cardiovascular comorbidities Manage them to improve symptoms/outcome.

18 Goals of Treatment A real clinical outcome should be something that patients and doctors care about Control of Symptoms Independent Living Reducing Morbidity (Hospitalization) Reducing Mortality Most Important? Least Important?

19 Randomised Controlled Trials ARB ACE-I CHARM-Preserved PEP-CHF I-PRESERVE Beta-blockers SENIORS DIURETICS Mainly MRAs LCZ696 Other treatments

20 Heart Failure (64% reduction) Placebo P< IndapamideSR ±perindopril Placebo IndapamideSR ±perindopril

21 PEP-CHF: Primary end-point at one year Proportion having an event (%) CV Death or HF Hosp P=0.01 at one year Placebo Perindopril 4mg 5 0 HR 0.69; 95% CI 0.47 to 1.01; p=0.055 Relative risk reduction -31% Time (mo) Patients at risk Perindopril Placebo

22 Cumulative Incidence of Primary Events (%) I-PRESERVE: Primary Endpoint Death or protocol specified CV hospitalization (Mean follow-up 49.5 months) HR (95% CI) = 0.95 ( ) Log-rank p=0.35 Placebo NT-proBNP 320 ( ) Placebo Irbesartan mg/day (mean 275mg/day) 10 - All Secondary Endpoints Neutral! 0 - No. at Risk Irbesartan Placebo Months from Randomization

23 I-PRESERVE Trial Effect of Irbesartan by baseline NT-proBNP median HR and 95% CI p-value Primary Endpoint All Patients (n=3480) Patients with NT-proBNP < median p=0.37 p=0.003 Patients with NT-proBNP > median Hospitalization for HF and Pump Failure Deaths p=0.47 All Patients (n=3480) Patients with NT-proBNP < median Patients with NT-proBNP > median p=0.68 p=0.001 p=0.19 Anand, Rector, Cleland et al Circ HF Hazard ratio

24

25 158 patients, post MI, LVEF > 40% At 32-month follow-up Propranolol caused a 35% significant reduction in total mortality However, Propranolol was discontinued because of adverse effects in 14% patients because of worsening CHF and hypotension

26 97 patients with symptoms and/or signs of HF, LVEF > 45% and DD. Carvedilol did not improve LVDD. There was a trend in worsening symptoms in Carvedilol group. LA size and BNP plasma levels significantly increased in Carvedilol group at 6/12.

27 245 patients (mean age 72, 58% men), LVEF > 40% were randomised to Carvedilol or placebo and followed up a mean of 3.2 years. Carvedilol did not improve prognosis of HFPEF patients Note: median prescribed dose was 7.5 mg/day.

28 Double-blind trial - 61 patients with HFPEF. Short term use of Ivabradine (7 days) has been shown to significantly decrease the post exercise LV filling pressures (E/E ), improving exercise capacity (peak Vo2) compared with placebo.

29 22 pts with HFpEF, randomised, X-over, Ivabradine vs placebo for 2 weeks Ivabradine reduced peak Vo2 (primary outcome) Circulation. 2015;132:

30

31 150 patients LVEF > 45% The use of diuretic (either loop diuretic or thiazide) quickly improved symptoms and quality of life. Significant biochemical (NTproBNP) and echocardiographic improvement at follow up with combined use of diuretic and ACE-I or ARBs.

32 422 patients with HFPEF Spironolactone improved echocardiographic findings (E/E ). However, changes in E/e were not associated with any clinical improvement. 6WMT, egfr and Hb levels decreased with Spironolactone!!!! Patients were too healthy (median NTproBNP 158 (IQR: ), 77 % grade I DD).

33

34 110 patients (57% women) with HFpEF (median NTproBNP ~ 240 ng/l) X-over: Isosorbide mononitrate (up to 120 mg/day) or placebo Results: nitrates decreased level of activity and did not improve QoL.

35 216 patients with HF, raised NTproBNP and LVEF > 50% Sildenafil (up to 60 mg tds) or placebo for 24 weeks Median NTproBNP ~ 700 ng/l Sildenafil did not improve exercise capacity or clinical status. Serious adverse events: 16% placebo vs. 22% Sildenafil

36 52 patients with HFpEF and raised PA pressure (mean PAP > 25 mmhg) Median NTproBNP ~ 1000 ng/l Randomised to sildenafil (up to 60 mg TDS) or placebo for 12 weeks Conclusions: sildenafil did not improve haemodinamics Adverse events: similar between placebo and sildenafil (>hypotension)

37 149 patients with HFpEF, NTproBNP>400 ng/l LCZ696 (up to 200 mg bd) vs valsartan (160 mg bd) for 36 weeks LCZ 696 was well tolerated. LCZ696 led to lower BP and smaller LA volume when compared to valsartan at 36m.

38 Conclusions Although we do not have much choice (yet). Try to characterize your patient Treat the underlying pathology (AF, HTN, T2DM, valvular disease, IHD, Anaemia) Consider you can make an incorrect diagnosis (and things worse)

HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2

HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2 HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old

More information

Therapeutic Targets and Interventions

Therapeutic Targets and Interventions Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium

More information

HFpEF, Mito or Realidad?

HFpEF, Mito or Realidad? HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY

More information

Heart Failure with Preserved EF (HFPEF) Epidemiology and management

Heart Failure with Preserved EF (HFPEF) Epidemiology and management Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se

More information

HFpEF: How to optimise management

HFpEF: How to optimise management HFpEF: How to optimise management Burkert Pieske M.D. Berlin, Germany Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, and Department of Internal

More information

Heart Failure A Disease for the Internist?

Heart Failure A Disease for the Internist? Heart Failure A Disease for the Internist? Dr Chris Davidson Sussex Cardiac Centre BRIGHTON UK Hot Topics in Heart Failure Drug treatments Valsartan / neprilysin inhib Investigations BNP and others Devices

More information

HF-Preserved Ejection Fraction

HF-Preserved Ejection Fraction HF-Preserved Ejection Fraction Justin A. Ezekowitz, MBBCh MSc FRCPC FACC FESC FAHA Associate Professor, University of Alberta Co-Director, Canadian VIGOUR Centre Cardiologist, Mazankowski Alberta Heart

More information

Diastolic Heart Failure Uri Elkayam, MD

Diastolic Heart Failure Uri Elkayam, MD Diastolic Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Diastolic Heart Failure Clinical Definition A

More information

INIBITORI NEPRILISINA

INIBITORI NEPRILISINA INIBITORI NEPRILISINA Marco Canepa, MD, PhD Università degli Studi di Genova Cardiologia, Ospedale Policlinico San Martino IRCCS marco.canepa@unige.it ARNI: ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS

More information

Nitrate s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT) A Randomized Clinical Trial

Nitrate s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT) A Randomized Clinical Trial Nitrate s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT) A Randomized Clinical Trial Margaret M Redfield On behalf of the NHLBI Heart Failure Clinical Research Network

More information

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Aldosterone Antagonism in Heart Failure: Now for all Patients? Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C

More information

HFpEF 2016 : Comorbidities and Outcomes

HFpEF 2016 : Comorbidities and Outcomes HFpEF 2016 : Comorbidities and Outcomes Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine, Duke University Editor in Chief, JACC: Heart

More information

Evidence of Baroreflex Activation Therapy s Mechanism of Action

Evidence of Baroreflex Activation Therapy s Mechanism of Action Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda

More information

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection

More information

Updates in Congestive Heart Failure

Updates in Congestive Heart Failure Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk

More information

Update on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy

Update on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored

More information

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF

More information

Vitals HR 90 BP 125/58 Tmax 98.7F O2 Sat 97% on NC 2L/min BMP SCr 1.78 K 3.9 Gluc 194 A1c 7.5 Cardiac LVEF 55% NTproBNP 9,200 Troponin 0.

Vitals HR 90 BP 125/58 Tmax 98.7F O2 Sat 97% on NC 2L/min BMP SCr 1.78 K 3.9 Gluc 194 A1c 7.5 Cardiac LVEF 55% NTproBNP 9,200 Troponin 0. ALDOSTERONE ANTAGONIST IN HEART FAILURE WITH PRESERVED EJECTION FRACTION ABBREVIATIONS BMP: basic metabolic panel HPI: history of present illness CAD: coronary artery disease HR: heart rate PINHUI (JUDY)

More information

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated) Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor

More information

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function:

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography

More information

Heart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France

Heart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p

More information

Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece

Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants

More information

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response

More information

Diagnosis is it really Heart Failure?

Diagnosis is it really Heart Failure? ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University

More information

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Diastolic HF DD: Diastolic Dysfunction DHF: Diastolic HF HFpEF: HF with preserved EF DD Pathophysiologic condition: impaired relaxation, LV compliance, LV filling

More information

HF-PEF: Symptoms, quality of life and mortality/morbidity

HF-PEF: Symptoms, quality of life and mortality/morbidity HF-PEF: Symptoms, quality of life and mortality/morbidity May 21, 2011 John McMurray, MD Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham & Women s Hospital Boston; Visiting Professor of Medicine,

More information

Heart Failure. GP Update Refresher 18 th January 2018

Heart Failure. GP Update Refresher 18 th January 2018 GP Update Refresher 18 th January 2018 Heart Failure Dr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British

More information

Drugs acting on the reninangiotensin-aldosterone

Drugs acting on the reninangiotensin-aldosterone Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School

More information

Faiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm

Faiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring

More information

New in Heart Failure SGK autumn session 2012

New in Heart Failure SGK autumn session 2012 New in Heart Failure SGK autumn session 2012 Roger Hullin Cardiology Department of Internal Medicine Centre Universitaire Hospitaler Vaudois University of Lausanne ESC Heart Failure Guidelines 2012 Classes

More information

The Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego

The Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart

More information

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17 Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies

More information

What to do for the Patient with Heart Failure and Preserved Ejection Fraction: HFpEF

What to do for the Patient with Heart Failure and Preserved Ejection Fraction: HFpEF What to do for the Patient with Heart Failure and Preserved Ejection Fraction: HFpEF Mariell Jessup MD, FAHA, FACC, FESC Professor of Medicine University of Pennsylvania Philadelphia, Pennsylvania Disclosure:

More information

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues

More information

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009 Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate

More information

SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016

SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016 SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016 Matthias Nägele, MD University Hospital Zurich Disclosures I have nothing to disclose. The new

More information

The Myths of Heart Failure with Preserved Ejection Fraction:

The Myths of Heart Failure with Preserved Ejection Fraction: The Myths of Heart Failure with Preserved Ejection Fraction: A misunderstood disease in search of a therapy Scott D. Solomon, MD The Edward D. Frohlich Distinguished Chair Professor of Medicine Harvard

More information

NT-proBNP: Evidence-based application in primary care

NT-proBNP: Evidence-based application in primary care NT-proBNP: Evidence-based application in primary care Associate Professor Rob Doughty The University of Auckland, Auckland City Hospital, Auckland Heart Group NT-proBNP: Evidence in Primary Care The problem

More information

Heart Failure in Women

Heart Failure in Women Heart Failure in Women Disclosure Professor Sindone has received honoraria, speaker fees, consultancy fees, is a member of advisory boards or has appeared on expert panels for: Professor Andrew Sindone

More information

Mihai Gheorghiade MD

Mihai Gheorghiade MD Mihai Gheorghiade MD Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois On behalf of: Stephen J Greene MD; Javed Butler MD MPH MBA; Gerasimos Filippatos

More information

Updates in Heart Failure (HF) 2016: ACC / AHA and ESC

Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc

More information

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function:

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography

More information

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center

More information

The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)

The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) 22 nd Annual Heart Failure 2018 an Update on Therapy April 21, 2018 Los Angeles, CA Barry Greenberg, M.D. Distinguished

More information

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the

More information

The Hearth Rate modulators. How to optimise treatment

The Hearth Rate modulators. How to optimise treatment The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,

More information

Management of Heart Failure from diagnosis to the grave. Richard Lawrance Consultant Cardiologist - WMH

Management of Heart Failure from diagnosis to the grave. Richard Lawrance Consultant Cardiologist - WMH Management of Heart Failure from diagnosis to the grave Richard Lawrance Consultant Cardiologist - WMH Case Presentation 55y man Breathless Ex tolerance 100yds on flat, limited by SOB No chest pain Borderline

More information

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:

More information

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern

More information

Ejection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction

Ejection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Keith Miller MD Diastolic Heart Failure Risk Factors Common Risk Factors Aging Female gender Obesity Hypertension Diabetes mellitus

More information

ACE inhibitors: still the gold standard?

ACE inhibitors: still the gold standard? ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University

More information

A patient with decompensated HF

A patient with decompensated HF A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,

More information

RAS Blockade Across the CV Continuum

RAS Blockade Across the CV Continuum A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)

More information

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies

More information

Therapeutic Targets and Interventions. Ali Valika, MD, FACC Advocate Medical Group

Therapeutic Targets and Interventions. Ali Valika, MD, FACC Advocate Medical Group Therapeutic Targets and Interventions Ali Valika, MD, FACC Advocate Medical Group Disclosures: 1. Novartis: Speaker Honorarium Diastolic Heart Failure Diastolic heart failure (DHF) is a major cause of

More information

Gerasimos Filippatos MD, FESC, FCCP, FACC

Gerasimos Filippatos MD, FESC, FCCP, FACC Gerasimos Filippatos MD, FESC, FCCP, FACC Head of HF Unit at Athens University Hospital, Greece President (2014-2016) of the HF Association of the European Society of Cardiology (ESC) Served as Chair of

More information

Heart failure in diabetes: consequences for diagnosis and therapy

Heart failure in diabetes: consequences for diagnosis and therapy Heart failure in diabetes: consequences for diagnosis and therapy Arno W. Hoes, MD, PhD (no potential conflict of interest regarding this presentation) Hartfalen werkgroep, Amersfoort, Maart 2017 Pathophysiology:

More information

The NEW Heart Failure Guidelines

The NEW Heart Failure Guidelines The NEW Heart Failure Guidelines Daily Practice HF scenario of the Case Presentations HF as a complex and heterogeneous syndrome Several proposed pathophysiological mechanisms involving the heart and the

More information

Heart Failure Update. Bibiana Cujec MD May 2015

Heart Failure Update. Bibiana Cujec MD May 2015 Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases

More information

Heart Failure Medical and Surgical Treatment

Heart Failure Medical and Surgical Treatment Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February

More information

Value of echocardiography in chronic dyspnea

Value of echocardiography in chronic dyspnea Value of echocardiography in chronic dyspnea Jahrestagung Schweizerische Gesellschaft für /Schweizerische Gesellschaft für Pneumologie B. Kaufmann 16.06.2016 Chronic dyspnea Shortness of breath lasting

More information

Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target

Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target JEFFREY S. BORER, M.D. Professor and Chairman, Department of Medicine and Chief, Division of Cardiovascular Medicine; Director,

More information

Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand

Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical

More information

Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham

Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Chronic heart failure

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST ESC Congress 2011 Pathophysiology of HFPEF Vascular Remodeling & Pulmonary Hypertension Carolyn S.P. Lam MBBS, MRCP, MS Case Presentation 81 yo woman with dyspnoea &

More information

Post Hoc Analysis of the PARADIGM Heart Failure Trial:

Post Hoc Analysis of the PARADIGM Heart Failure Trial: Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming

More information

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,

More information

HFpEF. April 26, 2018

HFpEF. April 26, 2018 HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes

More information

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities

More information

HEART FAILURE: PHARMACOTHERAPY UPDATE

HEART FAILURE: PHARMACOTHERAPY UPDATE HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis

More information

Heart Failure Clinician Guide JANUARY 2018

Heart Failure Clinician Guide JANUARY 2018 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.

More information

Heart Failure Clinician Guide JANUARY 2016

Heart Failure Clinician Guide JANUARY 2016 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,

More information

12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker

12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker 12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices Heart Rate as a Cardiovascular Biomarker Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine,

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

Heart rate lowering treatment in chronic heart failure

Heart rate lowering treatment in chronic heart failure Heart rate lowering treatment in chronic heart failure Jaromir Hradec 3rd Dept. Med., Charles Univ., Prague Czech Republic Things we knew, things we did Things we have learnt, things we should do What

More information

Dr.Fayez EL Shaer Consultant cardiologist Assistant professor of cardiology KKUH

Dr.Fayez EL Shaer Consultant cardiologist Assistant professor of cardiology KKUH Pulmonary Hypertension in patients with Heart Failure with Preserved Ejection Fraction Dr.Fayez EL Shaer Consultant cardiologist Assistant professor of cardiology KKUH Recent evaluation of available data

More information

Sleep Disordered Breathing and HH with Preserved Ejection Fraction:

Sleep Disordered Breathing and HH with Preserved Ejection Fraction: Sleep Disordered Breathing and HH with Preserved Ejection Fraction: Pr Thibaud DAMY Heart Failure Unit Department of Cardiology CHU Mondor, Créteil, France Definition of HF-PEF The diagnosis of HF-PEF

More information

The right ventricle in chronic heart failure

The right ventricle in chronic heart failure The right ventricle in chronic heart failure ESC 2012 Christian Opitz, Berlin There are no conflicts of interest relevant to this presentation Percent of Population Prevalence of Heart Failure by Age and

More information

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of

More information

The Dark Side of the Moon: Heart Failure with Preserved Ejection Fraction

The Dark Side of the Moon: Heart Failure with Preserved Ejection Fraction The Dark Side of the Moon: Heart Failure with Preserved Ejection Fraction Felix K. Yam, Pharm.D., M.A.S., BCPS-AQ Cardiology Associate Clinical Professor UC San Diego Skaggs School of Pharmacy and Pharmaceutical

More information

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20

More information

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg

More information

Dr Emma Copsey Consultant Cardiologist Glenfield Hospital 28 th September 2017

Dr Emma Copsey Consultant Cardiologist Glenfield Hospital 28 th September 2017 Dr Emma Copsey Consultant Cardiologist Glenfield Hospital 28 th September 2017 Educational Objectives Objectives To review the GIM & Cardiology syllabus for HF To review the new nomenclature/classification

More information

ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR

ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from

More information

Iron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD

Iron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD Iron Deficiency: New Therapeutic Target in Heart Failure Stefan D. Anker, MD PhD Department of Cardiology, Applied Cachexia Research, Charité Campus Virchow-Klinikum, Universitätsmedizin Berlin, Germany.

More information

New heart failure RCT: Update on BeAT-HF in the US

New heart failure RCT: Update on BeAT-HF in the US New heart failure RCT: Update on BeAT-HF in the US Michael R. Zile, MD Charles Ezra Daniel Professor of Medicine Medical University of South Carolina Chief, Division of Cardiology RHJ Department of Veterans

More information

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,

More information

Disclosure Information : No conflict of interest

Disclosure Information : No conflict of interest Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.

More information

UPDATES IN MANAGEMENT OF HF

UPDATES IN MANAGEMENT OF HF UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion

More information

TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018

TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018 TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018 Carlo Lombardi Cattedra di Cardiologia Università e Spedali Civili di Brescia All-cause mortality in the European

More information

Online Appendix (JACC )

Online Appendix (JACC ) Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis

More information

IVC Diameter in Patients With Chronic Heart Failure

IVC Diameter in Patients With Chronic Heart Failure JACC: CARDIOVASCULAR IMAGING VOL. 6, NO. 1, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcmg.2012.08.012 IVC

More information

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008 Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It

More information

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center

More information

heart failure John McMurray University of Glasgow.

heart failure John McMurray University of Glasgow. A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Probing prognosis in heart failure Daniel R. Wagner CHL/INCCI/CRP-Santé Luxembourg Disclosures Grants: Cordis, Boston Scientific, Medtronic, Sorin, Hexacath, Abbott,

More information

Biomarker-guided HF: What have we learned (so far)?

Biomarker-guided HF: What have we learned (so far)? Biomarker-guided HF: What have we learned (so far)? James L. Januzzi, Jr, MD, FACC, FESC Associate Professor of Medicine Harvard Medical School Director, Cardiac ICU Massachusetts General Hospital DECLARATION

More information

Highlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France

Highlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France Highlight Session 2014 Heart failure and cardiomyopathies Michel KOMAJDA Paris France # esccongress www.escardio.org/esc2014 HEART FAILURE AND CARDIOMYOPATHIES TOPIC 1 Drug Therapy TOPIC 2 Device Therapy

More information

Congestive Heart Failure: Outpatient Management

Congestive Heart Failure: Outpatient Management The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy

More information